Effects of propofol and isoflurane on haemodynamics and the inflammatory response in cardiopulmonary bypass surgery

British Journal of Biomedical Science

Volumn 72, Issue 3, 2015, Pages 93-101

  Sayed, S ^a   Idriss, N K ^a   Sayyed, H G ^a   Ashry, A A ^a   Rafatt, D M ^a   Mohamed, A O ^a   Blann, A D ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiopulmonary bypass; Hemoxygenase; Inflammation; Isoflurane; Propofol

Indexed keywords

C REACTIVE PROTEIN; CD11 ANTIGEN; CD18 ANTIGEN; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 6; INTERLEUKIN 8; ISOFLURANE; PROPOFOL; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3D RECEPTOR; HIF1A PROTEIN, HUMAN; HMOX1 PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IL6 PROTEIN, HUMAN; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANESTHESIA INDUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BYPASS SURGERY; CARDIOPULMONARY BYPASS; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART RATE; HEMODYNAMICS; HUMAN; INFLAMMATION; LENGTH OF STAY; LEUKOCYTE; MALE; MEAN ARTERIAL PRESSURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; BLOOD; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

ADULT; ANESTHETICS, INHALATION; ANESTHETICS, INTRAVENOUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD18; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOPULMONARY BYPASS; FEMALE; HEME OXYGENASE-1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERLEUKIN-6; INTERLEUKIN-8; ISOFLURANE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROPOFOL; RECEPTORS, COMPLEMENT 3D; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 84946219369     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2015.11666803     Document Type: Article

References (40)

1. Bernhard M, Schultz K, Hofer S et al. MIF and markers of the inflammatory response following cardiac surgery under extracorporeal circulation. Appl Cardiopulm Pathophysiol 2010; 14: 115-23.
2. Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 2005; 3 (2): 129-40.
3. Durandy Y. Minimizing systemic inflammation during cardiopulmonary bypass in the pediatric population. Artif Organs 2014; 38 (1): 11-8.
4. Warren OJ, Smith AJ, Alexiou C et al. The inflammatory response to cardiopulmonary bypass: part 1-mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009; 23 (2): 223-31.
5. Li S, Price R, Phiroz D, Swan K, Crane TA. Systemic inflammatory response during cardiopulmonary bypass and strategies. J Extra Corpor Technol 2005; 37 (2): 180-8.
6. Schneemilch CE, Hachenberg T, Ansorge S, Ittenson A, Bank U. Effects of different anaesthetic agents on immune cell function in vitro. Eur J Anaesthesiol 2005; 22 (8): 616-23.
7. Zhou R, Yang Z, Tang X, Tan Y, Wu X, Liu F. Propofol protects against focal cerebral ischemia via inhibition of microgliamediated proinflammatory cytokines in a rat model of experimental stroke. PLoS One 2013; 8; 9 (12): e82729.
8. Li Volti G, Basile F, Murabito P et al. Antioxidant properties of anesthetics: the biochemist, the surgeon and the anesthetist. Clin Ter 2008; 159 (6): 463-9.
9. Jaffer U, Wade RG, Gourlay T. Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth 2010; 2 (3): 161-75.
10. Mazoti M, Braz M, de Assis G et al. Comparison of inflammatory cytokine profiles in plasma of patients undergoing otorhinological surgery with propofol or isoflurane anesthesia. Inflamm Res 2013; 62 (10): 879-85.
11. Murphy GS, Szokol JW, Marymont JH, Avram MJ, Vender JS. The effects of morphine and fentanyl on the inflammatory response to cardiopulmonary bypass in patients undergoing elective coronary artery bypass graft surgery. Anesth Analg 2007; 104 (6): 1334-42.
12. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2000; 69 (4): 1192-7.
13. Wu Q, Purusram G, Wang H et al. The efficacy of parecoxib on systemic inflammatory response associated with cardiopulmonary bypass during cardiac surgery. Br J Clin Pharmacol 2013; 75 (3): 769-78.
14. Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J 2012; 31 (11): 2448-60.
15. Hölscher M, Schäfer K, Krull S et al. Unfavourable consequences of chronic cardiac HIF-1á stabilization. Cardiovasc Res 2012; 94 (1): 77-86.
16. Chen HB, Wang L, Jiang JF. Re-analysis of expression profiles for revealing new potential candidate genes of heart failure. Eur Rev Med Pharmacol Sci 2013, 17 (7): 903-11.
17. Idriss NK, Blann AD, Lip GY. Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol 2008; 52 (12): 971-8.
18. Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA 1994; 91 (13): 5987-91.
19. Chen YH, Lin SJ, Lin MW et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002; 111 (1): 1-8.
20. Dick P, Schillinger M, Minar E et al. Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease. Eur J Clin Invest 2005; 35 (12): 731-7.
21. Schmidt R, Tritschler E, Hoetzel A et al. Heme oxygenase-1 induction by the clinically used anesthetic isoflurane protects rat livers from ischemia/reperfusion injury. Ann Surg 2007; 245 (6): 931-42.
22. Gold MI, Sacks DJ, Grosnoff DB, Herrington CA. Comparison of propofol with thiopental and isoflurane for induction and maintenance of general anesthesia. J Clin Anesth 1989: 1 (4): 272-6.
23. Zgola K, Kulakowski P, Czepiel A et al. Haemodynamic effects of etomidate, propofol and electrical shock in patients undergoing implantable cardioverter-defibrillator testing. Kardiol Pol 2014; 72 (8): 707-15.
24. Korttila K, Ostman P, Faure E et al. Randomized comparison of recovery after propofol-nitrous oxide versus thiopentoneisoflurane-nitrous oxide anaesthesia in patients undergoing ambulatory surgery. Acta Anaesthesiol Scand 1990; 34 (5): 400-3.
25. Jeong CW, Ju J, Lee DW, Lee SH, Yoon MH. Lipid-emulsion propofol less attenuates the regulation of body temperature than micro-emulsion propofol or sevoflurane in the elderly. Yonsei Med J 2012; 53 (1): 198-203.
26. Liu TC. Influence of propofol, isoflurane and enflurance on levels of serum interleukin-8 and interleukin-10 in cancer patients. Asian Pac J Cancer Prev 2014; 15 (16): 6703-7.
27. Yoo YC, Shim JK, Song Y, Yang SY, Kwak YL. Anesthetics influence the incidence of acute kidney injury following valvular heart surgery. Kidney Int 2014; 86 (2): 414-22.
28. Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL. A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro-and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care 2008; 36 (1): 74-8.
29. Corcoran TB, Engel A, Sakamoto H, O'Shea A, O'Callaghan-Enright S, Shorten GD. The effects of propofol on neutrophil function, lipid peroxidation and inflammatory response during elective coronary artery bypass grafting in patients with impaired ventricular function. Br J Anaesth 2006; 97 (6): 825-31.
30. Baki ED, Aldemir M, Kokulu S et al. Comparison of the effects of desflurane and propofol anaesthesia on the inflammatory response and s100 protein during coronary artery bypass grafting. Inflammation 2013; 36 (6): 1327-33.
31. Hambsch J, Osmancik P, Bocsi J, Schneider P, Tárnok A. Neutrophil adhesion molecule expression and serum concentration of soluble adhesion molecules during and after pediatric cardiovascular surgery with or without cardiopulmonary bypass. Anesthesiology 2002; 96 (5): 1078-85.
32. Panik J, Baj Z, Moll JA et al. Effects of cardiopulmonary bypass on the expression of adhesive molecules in children undergoing cardiac surgery due to congenital heart disorders. Kardiol Pol 2004; 60 (2): 123-31. Discussion 132.
33. Tanaka T, Takabuchi S, Nishi K et al. The intravenous anesthetic propofol inhibits lipopolysaccharide-induced hypoxia-inducible factor 1 activation and suppresses the glucose metabolism in macrophages. J Anesth 2010; 24 (1): 54-60.
34. Yeh CH, Cho W, So EC et al. Propofol inhibits lipopolysaccharide-induced lung epithelial cell injury by reducing hypoxia-inducible factor-1alpha expression. Br J Anaesth 2011; 106 (4): 590-9.
35. Idriss NK, Lip GY, Balakrishnan B, Jaumdally R, Boos CJ, Blann AD. Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor. Thromb Haemost 2010; 104 (5): 1029-37.
36. Zheng H, Ma HP, Wang J, Ma M. Preoperative HO-1 levels as prognostic factor for adverse cardiac events in elder patients undergoing non-cardiac surgery. PLoS One 2013; 8 (3): e58567.
37. Hoetzel A, Schmidt R. Regulatory role of anesthetics on hemeoxygenase-1. Curr Drug Targets 2010; 11 (12): 1495-503.
38. Xia WF, Liu Y, Zhou QS, Tang QZ, Zou HD. Comparison of the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery. Yonsei Med J 2011; 52 (2): 326-32.
39. Gu J, Chi M, Sun X et al. Propofol-induced protection of SH-SY5Y cells against hydrogen peroxide is associated with the HO-1 via the ERK pathway. Int J Med Sci 2013; 10 (5): 599-606.
40. Xu J, Li H, Irwin MG et al. Propofol ameliorates hyperglycemiainduced cardiac hypertrophy and dysfunction via heme oxygenase-1/signal transducer and activator of transcription 3 signaling pathway in rats. Crit Care Med 2014; 42 (8): e583-94.